Table 4. Association of study characteristics and the pooled outcomes: univariate meta-regression analysis.

	RR of POAF incidence			WMD of LOH after surgery
	Coefficient	95% CI	p	Coefficient	95% CI	p
Number of patients	0.00007	−0.00026 to 0.00039	0.65	−0.00006	−0.00163 to 0.00151	0.93
Mean age (years)	0.03	−0.09 to 0.15	0.58	−0.09	−0.66 to 0.48	0.73
Male (%)	0.0009	−0.0414 to 0.0431	0.96	−0.009	−0.188 to 0.170	0.91
HTN (%)	−0.007	−0.028 to 0.013	0.44	−0.018	−0.070 to 0.034	0.43
DM (%)	−0.02	−0.06 to 0.02	0.48	−0.03	−0.11 to 0.06	0.51
CRF (%)	−0.008	−0.178 to 0.162	0.90	−0.03	−0.09 to 0.03	0.36
COPD (%)	−0.03	−0.07 to 0.01	0.19	−0.02	−0.13 to 0.08	0.57
Mean LVEF (%)	−0.003	−0.053 to 0.046	0.86	−0.12	−0.36 to 0.12	0.25
Mean LAD (mm)	0.07	−0.24 to 0.38	0.68	−0.12	−1.11 to 0.87	0.72
On β-blockers (%)	0.007	−0.004 to 0.018	0.17	0.06	−0.12 to 0.24	0.36
On ACEI/ARB (%)	0.004	−0.018 to 0.025	0.69	−0.003	−0.075 to 0.070	0.93
On statins (%)	0.01	−0.01 to 0.03	0.26	0.05	−0.02 to 0.12	0.19
Valvular surgery (%)	0.001	−0.008 to 0.011	0.74	−0.005	−0.048 to 0.038	0.78
Off-pump surgery (%)	−0.0004	−0.0155 to 0.0148	0.96	−0.0005	−0.0272 to 0.0261	0.96
Fish oil dose (g/d)	−0.08	−0.24 to 0.08	0.27	0.08	−0.91 to 1.08	0.85
EPA dose (g/d)	−0.09	−0.36 to 0.19	0.48	−0.24	−1.98 to 1.49	0.74
DHA dose (g/d)	−0.29	−0.50 to −0.08	0.03	−2.1	−4.0 to −0.2	0.04
EPA/DHA	0.48	−0.09 to 1.05	0.08	1.17	−0.25 to 2.59	0.12
POAF incidence in controls (%)	0.005	−0.014 to 0.024	0.58	0.006	−0.070 to 0.081	0.86
Jadad Score	0.05	−0.13 to 0.24	0.52	0.01	−0.75 to 0.77	0.97

RR, relative risk; POAF, post-operative atrial fibrillation; WMD, weighed mean difference; LOH, length of hospitalization; CI, confidence interval; HTN, hypertension; DM, diabetes mellitus; CRF, chronic renal failure; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; LAD, left atrial dimension; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; EPA, eicosapentaenoic acid; DHA, ducosahexaenoic acid.